Clinical Trials
27 results for Kidney/Renal Cancer
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- Condition: Renal Cell Carcinoma
- Intervention: Device: CyberKnife
- Study ID: NCT01890590
Phase II Clinical Trial of Docetaxel Plus Cisplatin as Adjuvant Chemotherapy and Concurrent Chemoradiotherapy Versus FOLFOX6 as Adjuvant and 5-FU/CF as Chemoradiotherapy in Patients of Locally Advanced Gastric Cancer After Radical Surgery
- Condition: Gastric Cancer
- Intervention: Drug: DC, Drug: concurrent chemoradiotherapy with 5-FU/CF, Radiation: adjuvant radiation
- Study ID: NCT01889303
Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders
- Condition: Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Synd
- Intervention: Procedure: Haploidentical Bone Marrow/Kidney
- Study ID: NCT01758042
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.
- Condition: Thyroid Cancer, Medullary
- Intervention: Drug: 177Lu-PP-F11N
- Study ID: NCT02088645
An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours
- Condition: Carcinoma, Neuroendocrine
- Intervention: Other: Lu-DOTA-TATE radiopharmaceutical
- Study ID: NCT01876771
Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer
- Condition: Breast Cancer, Breast Cancer Stage II-III
- Intervention: Drug: Docetaxel- Carboplatin
- Study ID: NCT01560663
Phase Ib Trial Of Pembrolizumab And Nintedanib
- Condition: Patients With Any Advanced Solid Tumors.
- Intervention: Drug: Nintedanib, Drug: Pembrolizumab
- Study ID: NCT02856425
A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers
- Condition: Neoplasms
- Intervention: Drug: JNJ-63723283
- Study ID: NCT02908906
Kidney Cancer DNA Registry
- Condition: Renal Cancer
- Intervention: Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable)
- Study ID: NCT02087852
A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)
- Condition: Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
- Intervention: Drug: cabozantinib, Drug: nivolumab
- Study ID: NCT03635892
Prospective Non-interventional Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment
- Condition: Advanced or Metastatic Renal Cell Carcinoma
- Study ID: NCT03647878
Preventive Effects of Low-dose Aspirin as Adjuvant Therapy After Radical Nephrectomy on Disease Recurrence/Metastasis and Survival in Patients With Locally Advanced Renal Cell Carcinoma: an Observational Prospective Cohort Study
- Condition: Aspirin as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma
- Intervention: Drug: Low dose of aspirin
- Study ID: NCT03734614
BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) - A Translational Study on Immunotherapy for Metastatic Renal Cancer
- Condition: Renal Cancer Metastatic
- Intervention: Biological: Immunological and tumour characterization
- Study ID: NCT03628859
Famitinib Malate Plus Anti-PD1 Therapy (SHR-1210) in Advanced Renal Cell Carcinoma, Urothelial Carcinoma, Advanced Cervical Cancer, Relapse Ovarian Cancer, Endometrial Cancer: Multi-institutional, Open-label, Phase 2 Trial
- Condition: Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer
- Intervention:
- Study ID: NCT03827837
Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers
- Condition: Clear Renal Cell Cancer (< 7cm Size)
- Intervention: Procedure: Partial or radical nephrectomy
- Study ID: NCT03694912
Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors
- Condition: Renal Tumor
- Intervention: Radiation: Stereotactic Ablative Radiotherapy
- Study ID: NCT03747133
Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies
- Condition: Clear Cell Renal Cell Carcinoma, Locally Advance Pancreatic Ductal Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Pancreatic Ductal Ad
- Intervention: Drug: ATR Kinase Inhibitor AZD6738, Drug: Olaparib
- Study ID: NCT03682289
A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partia
- Condition: Kidney Cancer, Prostate Cancer
- Intervention: Drug: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, Drug: 0.9% Sodium Chloride Injection
- Study ID: NCT03824808
A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib
- Condition: Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
- Intervention: Behavioral: Concomitant coaching
- Study ID: NCT03013946
An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse
- Condition: Renal Cell Carcinoma
- Intervention: Drug: Durvalumab, Drug: Tremelimumab
- Study ID: NCT03288532
A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma
- Condition: Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Intervention: Biological: Aldesleukin, Biological: Pembrolizumab
- Study ID: NCT03260504
Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study
- Condition: Advanced Renal Cell Carcinoma
- Intervention: Other: Carevive software
- Study ID: NCT03229083
Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma
- Condition: Kidney Cancer
- Study ID: NCT03414827
Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
- Condition: Renal Cell Carcinoma
- Intervention: Drug: Nivolumab, Drug: Axitinib
- Study ID: NCT03172754
Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
- Condition: Metastatic Renal Cell Carcinoma
- Intervention: Drug: Ipilimumab/ Nivolumab, Radiation: SBRT + Ipilimumab/Nivolumab
- Study ID: NCT04090710
REPLICA: Real Patient Life Treatment With Cabozantinib in Patients With Advanced or Metastatic RCC: A Descriptive and Prospective Non-Interventional Study
- Condition: Advanced or Metastatic Renal Cell Carcinoma
- Study ID: NCT04106349
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
- Condition: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell
- Intervention: Drug: Cabozantinib, Drug: Cabozantinib S-malate, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Radiation: Radium Ra 223 Dichloride
- Study ID: NCT04071223